Bio-Techne (NASDAQ: TECH) reported Q3 EPS of $0.53, $0.01 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $311.4 million versus the consensus estimate of $316.12 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.